Intellectual Disability, Anterior Maxillary Protrusion, and Strabismus

Executive Summary

MRAMS syndrome — Impaired Intellectual Development, Anterior Maxillary Protrusion, and Strabismus — is an ultra-rare autosomal recessive Mendelian disorder caused by biallelic loss-of-function mutation in SOBP (Sine Oculis-Binding Protein homolog, HGNC:29256), a nuclear zinc-finger transcriptional co-factor on chromosome 6q21. It was described in a single large consanguineous Israeli-Arab kindred and is characterized by severe intellectual disability, a distinctive dentofacial phenotype (anterior/vertical maxillary excess, open bite, crowded teeth), strabismus, and mild sensorineural hearing loss. Mouse orthologs (Sobp/Jxc1) recapitulate deafness and vestibular circling behavior, and SOBP's biochemical role as a Six1/Eya1 transcriptional modulator links it mechanistically to the broader branchio-oto-renal (BOR) developmental gene network.

1. Disease Information

Overview: MRAMS syndrome is a rare genetic multiple-congenital-anomaly/dysmorphic syndrome combining severe intellectual disability with a specific craniofacial (dentomaxillary) anomaly and ocular misalignment. It was first delineated as a distinct nosologic entity by Basel-Vanagaite et al. (2007), who could find "no similar disorder in the literature" and proposed the acronym MRAMS (Mental Retardation, Anterior Maxillary protrusion, and Strabismus) (PMID: 17618476).

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #613671 — "Impaired Intellectual Development, Anterior Maxillary Protrusion, and Strabismus; MRAMS" | | OMIM (gene) | *613667 — SOBP | | MONDO | MONDO:0013353 | | Orphanet | ORPHA:562559 — "Anterior maxillary protrusion-strabismus-intellectual disability syndrome" | | MedGen | UID 462274, Concept ID C3150924 | | HGNC (gene) | HGNC:29256 (SOBP) | | ICD-10/ICD-11 | No disease-specific code identified in the sources reviewed; as an ultra-rare congenital dysmorphic syndrome it would most likely be captured generically (e.g., under "other specified congenital malformation syndromes" categories) rather than by a dedicated rare-disease code — this is an inference, not a sourced code, and should be verified against the current ICD-11 rare-disease linearization before use. |

Synonyms: MRAMS syndrome; Mental retardation, anterior maxillary protrusion, and strabismus syndrome; Anterior maxillary protrusion, strabismus, intellectual disability syndrome.

Evidence basis: All clinical data derive from a single published aggregated case series (7 affected siblings within one extended consanguineous family), not from EHR-scale or population registries — this is a disease-level literature report, not an aggregated epidemiological resource.

2. Etiology

Disease causal factor: Purely genetic/monogenic. MRAMS is caused by homozygous truncating mutation in SOBP (Sine Oculis-Binding Protein homolog), identified by Birk et al. (2010): a c.1981C>T transition in exon 6, producing a premature stop codon at arginine residue 661 (p.Arg661Ter / R661X), truncating the last 212 amino acids of the 873-residue protein (PMID: 21035105).

"We report on the identification of a truncating mutation in the SOBP that is responsible for causing both syndromic and nonsyndromic ID in the same family." — Birk et al., 2010

Genetic risk factors: - Causal variant: SOBP c.1981C>T (p.R661X), homozygous, autosomal recessive. - Consanguinity is the dominant risk factor identified: the proband family's parents were first cousins of Israeli-Arab descent; 7 of 11 children were affected. - No modifier genes have been reported. Linkage analysis by Birk et al. (2010) excluded the SOBP locus in 22 additional unrelated families with syndromic intellectual disability, indicating SOBP mutations are not a common cause of similar phenotypes — this strongly implies extreme allelic/locus rarity rather than a recurrent mutational hotspot.

Environmental risk factors: None identified or applicable — MRAMS is a monogenic Mendelian disorder with no reported environmental or exposure-related contribution.

Protective factors: None reported (not applicable to a fully penetrant recessive truncating-null genotype in this pedigree).

Gene-environment interactions: None described; no evidence of environmental modulation of expressivity in the literature reviewed.

3. Phenotypes

Data are drawn from the original description of 7 affected siblings (Basel-Vanagaite et al., 2007) plus later re-analysis of the same kindred (Birk et al., 2010).

Onset/course: Congenital/early-childhood onset of intellectual disability and craniofacial features; the psychosis/epilepsy in the atypical sib was reported to emerge in adolescence, suggesting a distinct temporal trajectory possibly reflecting non-allelic or modified expression.

Important phenotypic heterogeneity noted by the authors:

"The child with MR but without a jaw anomaly was somewhat less severely retarded, had seizures and severe psychosis, which may point to his having a separate disorder." — Basel-Vanagaite et al., 2007

Birk et al. (2010) later showed this same individual does carry the SOBP truncating mutation, reframing this presentation as an allelic nonsyndromic ID phenotype rather than a separate disorder — i.e., SOBP mutation in this family produces both a syndromic (dysmorphic) and a nonsyndromic (epilepsy/psychosis, no dysmorphism) presentation.

Diagnostic exclusions performed in the original workup (informative negatives): normal brain MRI, normal standard karyotype, fragile X excluded, no subtelomeric rearrangements detected, random X-inactivation in the carrier mother (arguing against an X-linked mechanism before the AR/SOBP etiology was established).

Quality of life impact: Not formally studied (no EQ-5D/SF-36 data identified); qualitatively, severe ID plus visual (strabismus/amblyopia risk) and mild hearing impairment would be expected to substantially affect adaptive functioning, communication, and educational needs, consistent with general severe-ID QoL literature, though disease-specific QoL data do not exist.

4. Genetic/Molecular Information

Causal gene: SOBP (OMIM 613667; HGNC:29256), chromosome 6q21, ~171 kb genomic span (hg-coordinates approx. 107,490,106–107,661,306). Alias: JXC1 (Jackson circler protein 1, from its original identification via the mouse jc* mutant).

Gene structure: 7 exons in human (first 6 comprise the coding sequence); mRNA of 2,622 nt encodes an 873-amino-acid nuclear protein.

Protein domain architecture (from GeneCards/Wikipedia synthesis and Birk et al. 2010): - N-terminal nuclear localization signal (NLS) - Two FCS-type (MYM-type) zinc-finger motifs - A proline-rich region (PR1) - A putative RNA-binding motif region - A C-terminal NLS embedded within a second proline-rich motif (PR2) - GeneCards additionally notes reported SUMO1/SUMO2 interaction ("SUMO polymer binding" GO annotation)

Pathogenic variant identified: - c.1981C>T, p.R661X — homozygous nonsense/truncating variant, exon 6, removing the C-terminal ~212 residues (including part of the C-terminal NLS/PR2 region). Classification consistent with pathogenic per loss-of-function mechanism in an autosomal recessive disorder (formal ACMG/ClinVar classification not located in sources reviewed — recommend independent ClinVar/VarSome lookup before final curation). - Variant type: Nonsense (stop-gain). - Origin: Germline, homozygous, segregating with disease in a consanguineous pedigree. - Functional consequence: Loss-of-function via C-terminal truncation; per Tavares et al. (2021), the truncated R661X protein retains Six1-binding capacity, suggesting the pathogenic mechanism may be partial/hypomorphic rather than complete null, and may specifically disrupt only C-terminal-dependent functions (PMID: 34414417). - Allele frequency: Not reported in population databases (gnomAD/ExAC) in the sources reviewed — consistent with a private/founder variant in a single consanguineous kindred rather than a recurrent population variant; should be checked directly in gnomAD for completeness.

Modifier genes: None identified.

Epigenetic information: No DNA methylation/histone modification data specific to SOBP-related disease were identified in this search.

Chromosomal abnormalities: None — standard karyotype was normal in the original family; this is a single-gene sequence-variant disorder, not a copy-number/structural disorder.

5. Environmental Information

No environmental, toxin, lifestyle, or infectious contributory factors have been reported for MRAMS syndrome; it is described exclusively as a Mendelian autosomal recessive disorder arising from a single-gene defect. Not applicable.

6. Mechanism / Pathophysiology

Molecular pathway / protein function: SOBP functions as a nuclear transcriptional co-factor that modulates the SIX1–EYA1 transcriptional complex, a core regulatory node of the pre-placodal ectoderm/otic-vesicle developmental network (the same network implicated in branchio-oto-renal, BOR, spectrum disorders). Tavares et al. (2021) demonstrated:

"Sobp binds to and colocalizes with Six1 in the cell nucleus" and "significantly interferes with transcriptional activation of Six1+Eya1 target genes through competitive binding mechanisms," acting as "a transcriptional co-repressor that competes with Eya1 for Six1 binding in a dose-dependent manner." (PMID: 34414417)

Causal chain (proposed, integrating human and mouse data): 1. Trigger: Biallelic SOBP loss-of-function/truncating mutation (molecular scale) 2. Molecular dysregulation: Altered SOBP-mediated modulation of SIX1/EYA1 transcriptional output in developing neuroectodermal and otic/craniofacial tissues (molecular scale) 3. Cellular consequence — CNS: Disrupted gene expression programs during synaptogenesis in limbic-system neurons (cellular scale) 4. Cellular consequence — craniofacial: Disrupted patterning of neural-crest-derived cranial cartilage elements (Meckel's/ceratohyal cartilages, branchial arch cartilages) in the zebrafish/mouse craniofacial model (cellular/tissue scale) 5. Cellular consequence — inner ear: Disrupted cochlear growth, hair-cell fate specification, and patterning of the organ of Corti (tissue scale) 6. Organism-level phenotype: Severe intellectual disability, anterior maxillary protrusion/dentofacial anomaly, strabismus, mild sensorineural hearing loss (organism scale)

Cellular processes / brain expression: In situ studies in postnatal mouse brain show:

"Strong expression in the cortex, especially in layer V, the hippocampus, the piriform cortex, the mediodorsal nucleus of the thalamus, the anterior olfactory nucleus, and the mitral cell layer in the olfactory bulb" — i.e., limbic system structures — "at the time interval of active synaptogenesis" (Birk et al., 2010, PMID: 21035105).

This expression pattern is the proposed mechanistic link between SOBP disruption and cognitive/behavioral phenotypes (intellectual disability, and in the nonsyndromic sib, temporal lobe epilepsy and psychosis — both classically limbic-system-associated).

Inner ear mechanism (mouse model data, Kikkawa et al.): The vertebrate Sobp/Jxc1 ortholog was originally identified via positional cloning of the spontaneous mouse Jackson circler (jc) mutation:

"Jxc1/Sobp, Encoding a Nuclear Zinc Finger Protein, Is Critical for Cochlear Growth, Cell Fate, and Patterning of the Organ of Corti" — cellular patterning of the organ of Corti is severely disrupted in jc mutants, with supernumerary hair cells, mirror-image duplications of the tunnel of Corti and inner hair cells, and ectopic vestibular-like hair cells in Kölliker's organ (PMC2556235, Journal of Neuroscience 2008).

Craniofacial mechanism: Tavares et al. (2021) showed loss or overexpression of Sobp in model systems caused:

"severe cranial cartilage defects" including "deformed Meckel's and ceratohyal cartilages, hypoplastic branchial arch cartilages, and absent otic capsules" — providing a direct mechanistic bridge to the human dentofacial (maxillary) phenotype via disrupted neural-crest/pre-placodal patterning.

Suggested GO terms: - GO:0007605 (sensory perception of sound) - GO:0009952 (anterior/posterior pattern specification) / craniofacial developmental process terms - GO:0007416 (synapse assembly) / GO:0050808 (synapse organization) — relevant to the synaptogenesis-timed limbic expression - GO:0003713 (transcription coactivator activity) / GO:0003714 (transcription corepressor activity) — for the Six1/Eya1 modulatory role

Suggested CL terms: - CL:0000101 / specific inner-ear hair cell types (organ of Corti hair cells) - CL:0000540 (neuron) — cortical layer V pyramidal neurons, hippocampal neurons - Neural crest cell (CL:0000333) — for the craniofacial mechanism

Protein dysfunction: C-terminal truncation (loss of ~212 residues including part of the C-terminal NLS/proline-rich region) — a partial loss-of-function/hypomorphic mechanism, since Six1-binding is retained per Tavares et al.

Immune system involvement: None reported/applicable.

Metabolic changes, transcriptomics/proteomics/single-cell data: No disease-specific human -omics datasets were located; the available molecular data derive from candidate-gene Sanger sequencing (Birk et al., 2010) and mouse/zebrafish developmental-biology studies (Kikkawa et al.; Tavares et al.), not from large-scale human profiling.

7. Anatomical Structures Affected

Organ level: - Primary: Brain (limbic system — cortex, hippocampus, piriform cortex, thalamus, olfactory system); craniofacial skeleton (maxilla); eyes (extraocular muscle balance); inner ear (cochlea, vestibular apparatus) - Body systems: Nervous system, musculoskeletal/craniofacial system, ophthalmologic/visual system, auditory-vestibular system

Tissue/cell level: - Neural crest-derived craniofacial cartilage and bone (maxilla) - Cortical layer V neurons, hippocampal neurons, piriform cortical neurons (CNS) - Cochlear hair cells and supporting cells, spiral ganglion neurons, vestibular sensory epithelium (inner ear) - Extraocular muscles/oculomotor control circuitry (strabismus)

Subcellular level: Nucleus (SOBP is a nuclear protein; GO Cellular Component: nucleus, nuclear body) — consistent with its role as a transcriptional modulator.

Suggested UBERON terms: - UBERON:0002240 (spinal cord) — not directly relevant; more relevant: - UBERON:0002316 (hippocampal formation) - UBERON:0002012 (piriform cortex) - UBERON:0002420 (maxilla) - UBERON:0000982 (organ of Corti) / UBERON:0001846 (cochlea) - UBERON:0000970 (eye) / extraocular muscle structures

Lateralization: Not specifically reported; craniofacial and cochlear findings described as generally bilateral/symmetric in the mouse models; strabismus type not consistently specified as unilateral vs. bilateral in the human report.

8. Temporal Development

• Onset: Congenital/early childhood — intellectual disability and dentofacial features are apparent from early development; the atypical sib's seizures and psychosis emerged specifically in adolescence.
• Onset pattern: Insidious/developmental for the core ID and craniofacial phenotype; the psychiatric/seizure presentation in the one sib appears more subacute-onset in adolescence.
• Progression: Static/stable intellectual disability is typical of this class of Mendelian neurodevelopmental disorder (as opposed to a progressive neurodegenerative course) — this is inferred from the general "syndromic ID" framing rather than explicitly stated longitudinal follow-up data, since no long-term natural history study was located.
• Disease course/duration: Chronic, lifelong (both the ID and the craniofacial anomaly are structural/developmental, not remitting).
• Remission: Not applicable — no evidence for spontaneous remission of the core phenotype; psychosis/seizures in the atypical individual would follow standard chronic psychiatric/epilepsy management courses, but disease-specific outcome data were not located.
• Critical periods: The proposed mechanistic critical window is active synaptogenesis in postnatal limbic circuitry (per the mouse expression-timing data), suggesting this developmental window is mechanistically central to the neurocognitive phenotype, though this has not been translated into a defined human intervention window.

9. Inheritance and Population

• Inheritance pattern: Autosomal recessive, confirmed via consanguinity, homozygosity for the R661X SOBP variant, and segregation in the pedigree.
• Penetrance: Appears complete/high in the reported homozygotes, though only one family has ever been reported, limiting generalizability.
• Expressivity: Variable — the same homozygous genotype produced both the "syndromic" (dysmorphic, dentofacial + strabismus) phenotype in 6 sibs and a distinct "nonsyndromic" (no dysmorphism, but epilepsy + psychosis) phenotype in the 7th sib, a striking example of intrafamilial phenotypic variability at a single locus.
• Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not reported.
• Founder effect: The single reported family is of Israeli-Arab descent with parental consanguinity (first-cousin marriage); whether R661X represents a population founder allele beyond this kindred is unknown — no other families have been reported, and Birk et al. explicitly excluded the SOBP locus in 22 other syndromic-ID families, arguing against broad recurrence.
• Consanguinity: Central to the disease's emergence in this pedigree — first-cousin parents.
• Carrier frequency: Not established in any population database.

Epidemiology: - Prevalence: Extremely rare — to date, the disease has been described in only one extended family (7 affected individuals among 11 siblings). No prevalence estimate (cases per 100,000) exists; this is an ultra-rare/"cases in literature" tier disorder. - Incidence: Not calculable from available data. - Affected populations: Only the original Israeli-Arab consanguineous kindred has been reported. - Geographic distribution: Israel (single reported kindred); no other geographic clusters reported. - Sex ratio: Of the 7 affected sibs, 5 were female, 2 were male — though with such a small n, this is not interpretable as a true population sex-ratio signal, and autosomal recessive inheritance predicts equal sex distribution in principle.

10. Diagnostics

Clinical tests performed in the index family (all with normal/negative results, used to exclude alternative diagnoses): - Brain MRI — normal - Standard cytogenetic karyotyping — normal - Fragile X testing — excluded - Subtelomeric rearrangement screening — negative - X-inactivation studies in the carrier mother — random (arguing against skewed X-inactivation/X-linked mechanisms) - Biochemical/metabolic workup — normal (specific assays not detailed in sources reviewed)

Genetic testing: - Diagnostic confirmation is via identification of biallelic (homozygous or compound heterozygous) loss-of-function variants in SOBP — originally by Sanger sequencing/candidate-gene approach following linkage mapping; today this would be expected via exome sequencing (WES) or a targeted ID gene panel including SOBP. - Chromosomal microarray (CMA)/karyotype: Useful for excluding chromosomal etiologies (as done in the original workup) but not diagnostic for this single-gene disorder. - No SOBP-specific commercial single-gene test information beyond general genetic-testing-registry style listings was identified as authoritative in this pass (a "SOBP Gene ... NGS Genetic Test" listing appeared in search results from a commercial diagnostics lab site, but this is a vendor listing rather than a primary clinical-validity source and should not be cited as an evidence-based recommendation).

Clinical criteria: No formal consensus diagnostic criteria (DSM/ICD-style) exist; diagnosis rests on the combination of (a) severe ID, (b) anterior maxillary protrusion/dentofacial anomaly, (c) strabismus ± mild hearing loss, in the context of consanguinity, confirmed by SOBP molecular testing.

Differential diagnosis: Given the overlapping SOBP–SIX1/EYA1 mechanistic link, branchio-oto-renal (BOR) spectrum disorders (caused by SIX1/EYA1 mutations) are a biologically relevant differential/related mechanism to consider (per Tavares et al. 2021), though BOR's renal and branchial-cleft features are not part of the MRAMS clinical description. Other syndromic intellectual disability disorders with maxillary/dental anomalies and strabismus should also be considered and excluded by the workup pattern used in the index family (chromosomal, fragile X, subtelomeric, metabolic).

Screening: No population or newborn screening program exists for this ultra-rare disorder; in consanguineous families with a known SOBP variant, carrier testing and prenatal/preimplantation genetic testing would be the applicable reproductive-risk-reduction approach, though this is inferred from general practice for AR single-gene disorders rather than sourced to a MRAMS-specific guideline.

11. Outcome/Prognosis

• Survival/mortality: No mortality data reported; the disorder does not appear to be associated with reduced lifespan based on available reports (a chronic neurodevelopmental/dysmorphic syndrome rather than a progressive or lethal condition).
• Morbidity/function: Defined by severe intellectual disability (lifelong significant adaptive-functioning impairment), visual morbidity from strabismus (risk of amblyopia if untreated), and mild hearing impairment. The atypical sib's temporal lobe epilepsy and psychosis represent additional, potentially more impairing morbidity in that specific allelic presentation.
• Complications: Amblyopia risk from untreated strabismus; malocclusion-related dental/functional complications from the maxillary anomaly; psychiatric/seizure complications in the nonsyndromic presentation.
• Recovery potential: The core ID and craniofacial anomaly are structural/developmental and not expected to remit; symptomatic interventions (orthodontic/surgical, strabismus surgery, hearing amplification, seizure control, psychiatric treatment) can improve function but do not reverse the underlying condition.
• Prognostic factors: The presence vs. absence of the dentofacial dysmorphism appears to correlate with a different clinical trajectory within the same family (dysmorphic sibs had more severe ID without epilepsy/psychosis; the non-dysmorphic sib had somewhat less severe ID but developed epilepsy and severe adolescent-onset psychosis) — suggesting phenotypic heterogeneity may itself carry prognostic information, though this is based on an n of 1 for the atypical presentation and cannot be generalized.

12. Treatment

No disease-specific curative or targeted pharmacotherapy exists for MRAMS syndrome; management is symptomatic and multidisciplinary, inferred from standard management of the component phenotypes (no MRAMS-specific treatment trial or guideline was identified):

Experimental treatments: None identified; no MRAMS-specific clinical trials were found on searches of the available literature.

Pharmacogenomics: Not applicable/no data.

Treatment outcomes: No systematic outcome data (response rates, adverse events) specific to MRAMS management were identified — all inferred from general standard-of-care for the component phenotypes.

13. Prevention

• Primary prevention: Not applicable in the classic sense (a fully genetic AR disorder); the only actionable "primary prevention" lever is genetic/reproductive counseling in consanguineous families with a known carrier status, informing reproductive decision-making (carrier testing, prenatal diagnosis, preimplantation genetic testing) — standard practice for AR disorders, not MRAMS-specific literature.
• Secondary prevention: Early ophthalmologic screening/intervention for strabismus to prevent amblyopia; early audiologic screening for hearing loss; early developmental screening to initiate ID-related early intervention services.
• Tertiary prevention: Ongoing multidisciplinary management (dental/orthodontic, ophthalmologic, audiologic, neurodevelopmental, psychiatric as needed) to minimize functional complications.
• Genetic counseling: Directly relevant given the autosomal recessive inheritance and consanguinity in the index family — 25% recurrence risk per pregnancy for carrier couples.
• Immunization, public health, prophylaxis: Not applicable.

14. Other Species / Natural Disease

No naturally occurring MRAMS-like disease has been reported in non-human species. However, the causal gene has well-characterized induced/spontaneous laboratory mouse models (see Section 15) rather than natural veterinary disease. No OMIA (Online Mendelian Inheritance in Animals) entry or veterinary case series was identified for SOBP-associated disease.

Orthologous gene: Mouse Sobp (a.k.a. Jxc1), MGI:1924427, chromosome 10 (cytogenetic band 10qB2), ~172 kb, 864-amino-acid protein — high conservation of domain structure (NLS, FCS-zinc fingers, proline-rich regions) with human SOBP.

Comparative pathology: The mouse cochlear/vestibular phenotype (see below) is considered a reasonable model for the human mild hearing-loss component but does not recapitulate the craniofacial (maxillary) or cognitive/behavioral phenotype in a directly comparable way — this represents a human-model mismatch worth flagging for any curated entry (i.e., mouse data strongly support the auditory-vestibular mechanism but translational fidelity to the human dentofacial and cognitive phenotype is comparatively less direct, since it is the zebrafish/mouse craniofacial-cartilage work of Tavares et al., not the jc/jc2J mouse itself, that addresses the craniofacial mechanism).

Zoonotic potential/transmission: Not applicable (non-infectious genetic disorder).

15. Model Organisms

Mouse models (genetic, spontaneous):

1. Jackson circler (jc) mouse — spontaneous recessive mutation, 10-bp deletion in exon 6 of Sobp, causing a frameshift and premature stop codon at residue 490. Phenotype: profound deafness, erratic circling (vestibular) behavior, and severe disruption of organ of Corti patterning — supernumerary outer hair cells, duplicated tunnel of Corti, ectopic vestibular-like hair cells in Kölliker's organ, and smaller/thicker vestibular end organs (Kikkawa et al., Journal of Neuroscience 2008, PMC2556235; related earlier positional-cloning work in Human Molecular Genetics/associated cochlear-development literature). Strain resource: Jackson Laboratory strain 000563.

   "Jxc1/Sobp, Encoding a Nuclear Zinc Finger Protein, Is Critical for Cochlear Growth, Cell Fate, and Patterning of the Organ of Corti"

2. jc2J allele — independent spontaneous nonsense mutation, c.1894G>T, creating a premature stop codon at residue 632 — phenotypically similar deafness/circling.

Model characteristics: - Phenotype recapitulation: Excellent for the auditory-vestibular component (deafness, cochlear/organ-of-Corti dysmorphogenesis) — directly informative for the human "mild cochlear hearing loss" feature, though the mouse phenotype (profound deafness) is considerably more severe than the human "mild" hearing loss, an important severity mismatch to note. - Model limitations: Does not, by itself, model the human intellectual disability, craniofacial (maxillary), or ocular (strabismus) phenotypes; those are informed instead by expression-pattern data (limbic system in postnatal mouse brain) and by separate craniofacial-development models (zebrafish/mouse Sobp-Six1 work by Tavares et al., 2021) rather than by the jc/jc2J deafness-circling model directly.

Applications: The jc/jc2J models are used to study cochlear developmental biology and hair-cell fate specification; the Tavares et al. craniofacial model system is used to study Six1/Eya1-dependent neural crest and pre-placodal ectoderm patterning relevant to both BOR spectrum disorders and the MRAMS dentofacial phenotype.

Resources: MGI:1924427 (mouse Sobp gene page); JAX strain 000563 (Jackson circler).

Summary of Key Citations

1. Basel-Vanagaite L, Rainshtein L, Inbar D, Gothelf D, Hennekam R, Straussberg R. "Autosomal recessive mental retardation syndrome with anterior maxillary protrusion and strabismus: MRAMS syndrome." Am J Med Genet A. 2007;143A(15):1687-91. PMID: 17618476.
2. Birk E, et al. "SOBP is mutated in syndromic and nonsyndromic intellectual disability and is highly expressed in the brain limbic system." Am J Hum Genet. 2010;87(5):694-700. PMID: 21035105. DOI: 10.1016/j.ajhg.2010.10.005.
3. Kikkawa Y, et al. "Jxc1/Sobp, Encoding a Nuclear Zinc Finger Protein, Is Critical for Cochlear Growth, Cell Fate, and Patterning of the Organ of Corti." J Neurosci. 2008;28(26):6633. PMC2556235.
4. Tavares ALP, et al. "Sobp modulates the transcriptional activation of Six1 target genes and is required during craniofacial development." Development. 2021;148(17):dev199684. PMID: 34414417.
5. OMIM #613671 — Impaired Intellectual Development, Anterior Maxillary Protrusion, and Strabismus; MRAMS.
6. OMIM *613667 — Sine Oculis-Binding Protein Homolog; SOBP.
7. MedGen C3150924.
8. Orphanet ORPHA:562559.
9. GARD/GeneReviews summary — Intellectual disability, anterior maxillary protrusion, and strabismus.
10. SOBP — Wikipedia.

Notes on evidence gaps (explicit, per curation discipline): This is a single-family, single-publication-lineage disorder. No independent replication family has been reported; no population prevalence, gnomAD allele frequency, natural-history/longitudinal study, disease-specific QoL instrument, clinical trial, or ICD-11 code was located. Several candidate ontology term IDs above (particularly for "anterior maxillary protrusion," "open bite," "dental crowding," and "temporal lobe epilepsy") could not be confirmed with certainty via the searches performed in this pass and must be verified against the authoritative HPO/OAK lookup before being committed to any curated knowledge base entry, consistent with this project's anti-hallucination review standard.